Swiss drugs in China is much cheaper

With massive price international pharmaceutical companies want to boost discounts your business in the billion market of China. Manufacturers such as the Swiss companies Roche and Novartis have agreed to price reductions of an average of 61 percent, to reach a list with drugs that are reimbursed by the state, as the Supervisory authority, the National Healthcare Security Administration (NHSA) announced on Thursday.

To the 70 new medicines that come on the list include, among others, the Roche breast cancer drug Perjeta and the eczema middle of Omalizumab by Novartis. Almost all of the new substances on the list would be the "world's lowest prices", said the NHSA. Chinese patients can be a significant part of the costs for the drugs on the list of the national health insurance refund.

Thus the pharmaceutical manufacturers are likely to your sales volume, especially in smaller and less well-to-do increase Chinese cities. "China is the ultimate market remains with high volume and low prices, and so international companies have the feeling that you must make large price reductions to volume," said Brad Loncar of asset managers Loncar Investments. Industry experts pointed also to the danger that the manufacturer criticism from other markets could, if you want to grant discounts in China high price.

Roche had already benefited in recent months from a strong business with anti-cancer drugs in rural regions of China. (red/sda)

Created: 28.11.2019, 14:54 PM